1. Home
  2. CYTK vs SON Comparison

CYTK vs SON Comparison

Compare CYTK & SON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • SON
  • Stock Information
  • Founded
  • CYTK 1997
  • SON 1899
  • Country
  • CYTK United States
  • SON United States
  • Employees
  • CYTK N/A
  • SON 28000
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • SON Containers/Packaging
  • Sector
  • CYTK Health Care
  • SON Consumer Discretionary
  • Exchange
  • CYTK Nasdaq
  • SON Nasdaq
  • Market Cap
  • CYTK 4.4B
  • SON 4.6B
  • IPO Year
  • CYTK 2004
  • SON N/A
  • Fundamental
  • Price
  • CYTK $38.62
  • SON $46.19
  • Analyst Decision
  • CYTK Buy
  • SON Strong Buy
  • Analyst Count
  • CYTK 13
  • SON 8
  • Target Price
  • CYTK $71.58
  • SON $57.63
  • AVG Volume (30 Days)
  • CYTK 1.4M
  • SON 1.0M
  • Earning Date
  • CYTK 08-07-2025
  • SON 07-23-2025
  • Dividend Yield
  • CYTK N/A
  • SON 4.61%
  • EPS Growth
  • CYTK N/A
  • SON 50.18
  • EPS
  • CYTK N/A
  • SON 5.59
  • Revenue
  • CYTK $85,738,000.00
  • SON $6,337,597,000.00
  • Revenue This Year
  • CYTK $27.08
  • SON $46.12
  • Revenue Next Year
  • CYTK $652.09
  • SON $0.72
  • P/E Ratio
  • CYTK N/A
  • SON $8.24
  • Revenue Growth
  • CYTK 2635.74
  • SON 37.96
  • 52 Week Low
  • CYTK $29.31
  • SON $39.46
  • 52 Week High
  • CYTK $59.39
  • SON $56.77
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 60.89
  • SON 52.08
  • Support Level
  • CYTK $32.89
  • SON $44.62
  • Resistance Level
  • CYTK $36.79
  • SON $46.63
  • Average True Range (ATR)
  • CYTK 1.73
  • SON 0.91
  • MACD
  • CYTK 0.15
  • SON 0.00
  • Stochastic Oscillator
  • CYTK 91.77
  • SON 55.34

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About SON Sonoco Products Company

Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.

Share on Social Networks: